Topics:

Genitourinary Cancers

Genitourinary Cancers

Too many people are being screened, diagnosed, and treated for certain types of cancer, according to two cancer researchers.

Adding cixutumumab to ADT did not significantly increase the undetectable PSA rate in men with newly diagnosed metastatic hormone-sensitive prostate cancer.

This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

A combination of biomarkers has shown promise as a surrogate for survival in clinical trials of metastatic castration-resistant prostate cancer.

A new study suggests that men with a history of cardiovascular disease prior to starting ADT are at risk for such events during the first 6 months of treatment.

At this year’s ASCO GU Cancers Symposium, several high-impact and potentially practice-changing abstracts were presented during the prostate cancer session.

A reduction in testosterone levels in the first year of ADT correlates with improved survival in prostate cancer patients being treated for biochemical failure.

Pages

Subscribe to Genitourinary Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.